No abstract

Context: Hepatitis C, as a major public health problem, has serious complications and drug users are the highest risk group for it.Objectives: As the importance of this subject, the current study has been done to estimate the pooled prevalence  and distribution of hepatitis c virus in Iranian Drug User.Evidence Acquisition: Articles were identified through international searching databases including PubMed, Scopus, Elsevier, Google Scholar and Web of Science and Iranian scientific information database (SID), Health. barakatkns, IranDoc, Civilica and MagIran. We reviewed systematically all studies reporting the prevalence of HCV Iranian Drug User.Results: 227 records were identified by the electronic search, of which 62 studies were identified as relevant  papers which were meta-analyzed for the pooled HCV prevalence. Overall, prevalence of HCV  was 42.01 %( 36.83%-47.20%) in Iranian drug user.Conclusion: Our meta-analysis study showed that HCV prevalence is high in drug users in Iran. With respect to the high prevalence of Hepatitis C among Drug User, ongoing preventive actions for this group are recommended.

Context: The prevalence of in-hospital death due to COVID-19 hospital is one of the qualitative indexes, which can be used to assess the quality of care, as well as the mortality patterns in COVID-19 pandemic.Objectives: Therefore, this systematic and meta-analysis study has been done with the aim of estimating overall prevalence in-hospital death due to COVID-19 disease in iranian patients Evidence Acquisition: Articles were identified through international searching databases including PubMed, Scopus, Elsevier, Google Scholar, and Web of Science and Iranian scientific information database (SID), Health.barakatkns, IranDoc, Civilica and MagIran. We reviewed systematically all studies reporting the prevalence of in-hospital death due to COVID-19 disease. In this study meta-analysis method with random effect model has been used to estimate the pooled prevalence. Results: 118 records were identified by the electronic search, of which 43 studies were identified as relevant papers that were meta-analyzed for the pooled in-hospital death due to COVID-19 prevalence. Overall, prevalence of death were 12.16% (95% CI: 10.72%-13.61%). The highest and lowest death prevalence has been reported in Northern Provinces (Gilan, 27.27% (95% CI: 8.66%-45.88%) and Mazandaran, 21.27% (95% CI: 18.14%-24.40%)) and Turkish-speaking provinces (Azerbaijan, East, 3.29% (95% CI: 2.11%-4.47%) and Zanjan, 3.42% (95% CI: 1.82%-5.02%)) respectively. Conclusions: Considering the death rate obtained in this study and its comparison with other countries, it can be said that the performance of the Iranian medical system in COVID-19 pandemic is acceptable.